Comparing Bioequivalence of Two Semaglutide Formulations in Overweight or Obese Individuals

This study focuses on comparing two different forms of a medication called semaglutide in individuals with overweight or obesity. The goal is to understand how these two forms of semaglutide are absorbed and remain in the bloodstream after injection. Neither form is currently approved for treating obesity. Participants will receive one of the two forms, determined by chance. The study is important as it may help develop a more effective treatment approach for overweight or obesity, potentially improving care for those affected by these conditions. Participants will administer the medication as a weekly injection under the skin of the stomach, using a pen-injector. The type of pen-injector varies between the two forms of semaglutide. Participants will be taught how to self-inject, practicing with a placebo (dummy medication) beforehand. The study lasts approximately 27-30 weeks, with 25 visits to the study doctor. Two visits require a 3-day, 2-night stay in the clinic. Participants will receive a total of 21 injections. If the study doctor identifies potential health risks, a participant may need to withdraw. Pregnant women, breastfeeding women, or those planning pregnancy during the study period cannot participate.